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The most serious complication of treatment with coagulation
factor concentrates in patients with congenital hemophilia is
development of alloantibodies against the deficient coagula-
tion factor (F), namely, VIII (FVIII; hemophilia A) or IX (FIX;
hemophilia B).1–5 Indeed inhibitory alloantibodies, which
develop in up to one-third of previously untreated patients
with severe hemophilia A and up to 5 to 6% of patients with
severe hemophilia B, neutralize the coagulant effect of factor
replacement therapy, therefore requiring a shift toward treat-
ments based on FVIII- and FIX-bypassing agents.6–8 As a
consequence, inhibitors preclude the access of persons with
hemophilia to safe and effective standards of care, predispos-
ing them to increased risk of morbidity and permanent dis-
ability which, ultimately, negatively influences their quality of
life.7 The management of hemophilia A patients with inhibi-
tors is particularly challenging for physicians operating at
hemophilia treatment centers (HTCs), as they are frequently
forced to make critical decisions based on their own experi-
ence rather than on evidence-based data.9 Due to the heavy
social, health, and economic burden of inhibitors,3 it is not
surprising that several investigators have devoted their re-
search in the last decade on understanding the pathogenic
mechanisms of inhibitors to predict and, possibly, prevent
their development.9 However, while such investigation has
been focusedmainlyonpatientswithhemophiliaAandB, little
isknownpertaining to the inhibitors occurring inpersonswith
the rarer congenital bleeding disorders due to defects of the
other clotting factors. In this narrative review, we summarize
the current knowledge on alloantibodies complicating repla-
cement treatment in patients with inherited deficiency of
coagulation FV, FVII, FXI, and FXIII. Alloantibodies occurring
against vonWillebrand factor in patientswith vonWillebrand
disease and patients with Glanzmann’s thrombasthenia and
other inherited platelet disorderswill not bediscussedhere, as
these are the subjects of two other reviews in this issue of the
journal.10,11
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Abstract Themost worrying complication of replacement therapy for severe hemophilia A and B
is currently the occurrence of inhibitory alloantibodies against infused factor VIII and
factor IX, respectively. Inhibitors compromise the management of hemorrhage in
affected patients, with a considerable increase in complications, disability, and costs.
While these alloantibodies have been extensively studied in the past years in
hemophilia A and B, those occurring in patients with other inherited bleeding disorders
are less well characterized and still poorly understood, mostly due to the rarity of these
hemorrhagic conditions. This narrative review will deal with inhibitors arising in
patients with inherited bleeding disorders other than “classical” hemophilia, focusing
in particular on those developing in patients with congenital deficiency of coagulation
factor V, factor VII, factor XI, and factor XIII.
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Search Methods
We reviewed the medical literature for published studies on
alloantibodies in patients with inherited bleeding disorders
other than hemophilia A or hemophilia B. The MEDLINE
electronic database was searched without temporal limits
using English language restriction. The Medical Subject
Heading and key words used were: “alloantibodies,” “inhi-
bitors,” “inherited,” “congenital,” “bleeding disorders,” “he-
morrhagic disorders,” “coagulation factors deficiency,”
“factor V (FV),” “factor XI (FXI),” “factor VII (FVII),” and “factor
XIII (FXIII).” We also screened the reference lists of most
relevant review articles for further studies not captured in
our initial literature search. Search terms were also applied
to abstracts from the latest international congresses on
hemostasis and thrombosis and hematology.
Alloantibodies in Congenital FV Deficiency
Characteristics of Congenital FV Deficiency
FV is a 249 kDa glycoprotein encoded by F5 gene located on
chromosome 1 and synthesized by megakaryocytes and he-
patocytes.12 Approximately 20% of circulating FV is contained
in platelets.13 Once activated by thrombin, FVa acts as a
cofactor for FXa in the conversion of prothrombin to throm-
bin.14 Notably, as FV also downregulates FVIII activity, an FV
deficiency may result in a thrombotic tendency.15,16 Most
cases of FV deficiency are characterized by the concomitant
deficiency of FV activity and antigen levels (type I deficiency),
while a quarter of themhave normal antigen levels, suggesting
the presence of a dysfunctional protein (type II deficiency).12
FV deficiency is inherited in an autosomal recessive manner
and has an estimated prevalence of approximately
1:1,000,000.17–19 The first causative mutation in the F5 gene
leading to a severe FV deficiency was discovered nearly
20 years ago20 and there are currently more than 200 cases
described so far withmore than 100DNAalterations reported,
including nonsense and missense mutations, insertions, dele-
tions, and splice-site mutations.21 Two-thirds of all mutations
causing FV deficiency are nonsense mutations in the FV gene.
One-third of mutations causing FV deficiency introduce pre-
mature stop codons in the FV gene, either as nonsense muta-
tions or as small out-of-frame insertions or deletions. Many
new missense mutations, clustered in the A and C domains,
have been described in recent years and now represent nearly
50% of all reported mutations. In most cases, these mutations
affect secretion of FV, thus substantially reducing antigen
levels (type I deficiency).21 The fact that most patients carry
a unique mutation which is not found in other FV-deficient
patients confirms the remarkable allelic heterogeneity of this
disease.22 The initial identification of congenital FV deficiency
maybebasedonthedemonstrationof theprolongationofboth
prothrombin time (PT) and activated partial thromboplastin
time (aPTT), and the diagnosis by identification of reduced FV
activity, usually determined by modified one-stage PT-based
clotting assays. To distinguish qualitative from quantitative FV
deficiency, aplasmaFVantigendeterminedby immunoassay is
required.23Congenital FVdeficiencycanbedistinguished from
acquired FV deficiency, inmost cases due to FVautoantibodies
occurring after exposure to bovine FV present in topical
thrombin,24 by noncorrection in PT and aPTT mixing studies
in subjects without previous bleeding history.
Frequent symptoms in patients with FV deficiency are
epistaxis and menorrhagia, which occur in approximately
50% of cases. Other, less common symptoms, include hemar-
throses and hematomas, which occur in approximately 25%
of patients, whereas life-threatening episodes in the central
nervous system and gastrointestinal tract are rare (6%).25–27
Pertaining to the treatment, there is no FV concentrate
available, and FV is not present in significant amount in
cryoprecipitate or prothrombin complex concentrates.28 Thus,
replacement therapyof FV is onlyachieved through fresh frozen
plasma, preferably virus inactivated.29–34 Due to their relative
content of FV, platelet transfusions have also been successfully
used for the management of FV-deficient patients.35
Anti-FV Alloantibodies
Development of alloantibodies against infused FV is a potential
complication of replacement therapy with fresh frozen plasma
in patients with severe congenital FV deficiency.28 Although
very few cases have been reported in the literature so far,36–41
the incidence of this adverse event could be underestimated,
especially if low-titer transient inhibitors are considered.42 For
instance, Fratantoni and colleagues36 described an 8-year-old
girl with hereditary FV deficiency who developed an IgG class
anti-FV alloantibody after treatment with fresh frozen plasma
for several years. It is, however, possible that the FV inhibitor
developed earlier, during the first few plasma transfusions,
because of a noted initial partial correction of prolonged
coagulation profile after fresh frozen plasma transfusions.
Subsequently, as the inhibitor titer increased, more frequent
plasma transfusions failed to improve the prolonged PT and
aPTT. Similarly, Mazzucconi and colleagues37 reported the case
of a female patient with severe congenital FV deficiency who
became refractory to plasma infusion due to the development
of a low-titer anti-FV antibody. Salooja and colleagues38 re-
ported another case of neonatal intracranial hemorrhage asso-
ciated with severe congenital FV deficiency complicated by an
FV inhibitor (0.6 Bethesda units [BU]), successfullymanaged by
solvent detergent-treated fresh frozen plasma and platelet
concentrate infusion. Lee and colleagues39 reported the
dramatic case of an 18-day-old Indian infant with severe FV
deficiency and FV inhibitor (2.4 BU) with intracranial hemor-
rhage.Repeated transfusionsof fresh frozenplasmaandplatelet
concentrates, administrations of immunosuppressive therapy
(prednisolone and cyclophosphamide), and intravenous im-
munoglobulin (IVIG) failed to normalize the coagulation
profiles. Exchange transfusion followed up by administrations
of activated prothrombin complex and transfusions of fresh
frozen plasma and platelet concentrates caused a temporary
normalization of coagulation profile, enabling an insertion of a
ventriculoperitoneal shunt for progressive hydrocephalus. The
treatment was, however, complicated by thrombosis of the left
brachial artery and the child finally died from another episode
of intracranial hemorrhage 10 days thereafter. Divanon and
colleagues40 reportedthecaseofa19-year-oldmanwithsevere
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congenital FV deficiency and a high-titer (6 BU) inhibitor who
was treated with single donor leukocyte-depleted platelet
concentrate with a consequent anamnestic response (FV in-
hibitor rose up to 30 BU). Thus, the patient was successfully
treated with recombinant activated factor VII (rFVIIa, bolus
injections of 80 μg/kg at 3 hourly intervals on the first day, at
4 hourly intervals on the second day and then two daily
boluses). Finally, Perez Botero and colleagues41 described the
case of a 67-year-old man with congenital FV deficiency and a
high-titer FV inhibitor level with recurrent gastrointestinal
bleedingdue to arteriovenousmalformations successfully trea-
ted with thalidomide after endoscopic, hemostatic (activated
prothrombin complex concentrate), and hormonal (danazol)
treatment failed. As immune tolerance induction (ITI) treat-
ment was impracticable due to the high dose of fresh frozen
plasma required, an alternative approach with high-dose cor-
ticosteroidsandrituximabwasattempted, resulting in inhibitor
eradication.
In summary, the data available on the characteristics of
alloantibodies against infused FV in congenital FV deficiency
are scanty (►Table 1), and most information regarding
their management are derived from reports of acquired FV
inhibitors.43–45 Thus, for inhibitor eradication, various immu-
nosuppressive agent-based protocols have been suggested.45
Pertaining to the treatment of bleeding, a large volumeof fresh
frozen plasma, necessary to overcome the inhibitor and pro-
duce an effective hemostatic effect, and platelet concentrates
represent the mainstay of the treatment of bleeding in these
complicated cases. In particular, transfusion of platelet con-
centrates should be considered as initial therapy, considering
that FV in platelets, unlike that circulating in plasma, is
protected from the neutralization of the antibody, being
delivereddirectly to the site of injury.46,47Also, the transfusion
of platelets decreases the risk of circulatory overload asso-
ciated with the transfusion of the large volume of plasma. In
patients, refractory to repeated platelet transfusions, the
administration of rFVIIa could be beneficial.40 The main ad-
vantages of this recombinant hemostatic agent in such clinical
setting include the efficacy being independent of the inhibitor
titer and the lack of anamnestic response. In patients with a
life-threatening bleeding tendency, an immediate reduction of
the FV inhibitor titer by immunoadsorptionor plasmapheresis
with subsequent administrationof fresh frozenplasmawithor
without platelet concentrates might be the best therapeutic
approach.
Alloantibodies in Congenital FVII Deficiency
Characteristics of Congenital FVII Deficiency
Factor VII is a 50 kDa vitamin K-dependent glycoprotein that
circulates inplasma in two forms (99%asa single chain inactive
form and 1% as an active two-chain form). FVII, encoded by the
F7gene locatedonchromosome13,playsa fundamental role in
the initiation of coagulation through its interactionwith tissue
factor.48,49 FVII deficiency is inherited with an autosomal
recessive pattern (estimated prevalence 1:500,000).49 Circu-
lating levels of FVII coagulant activity (FVII:C) and FVII antigen
(FVII:Ag) are influenced by several genetic and nongenetic
factors (age, sex, cholesterol, and triglyceride levels), and it is
also well known that FVII polymorphisms modulate FVII
levels.50 Most patients have concomitantly low levels of FVII:
C and FVII:Ag (type 1), but other cases are characterized by
normal or moderately low levels of FVII:Ag and much lower
levelsofFVII:C (type2).51ThemolecularbasisofFVIIdeficiency
Table 1 Main characteristics and management of alloantibodies in congenital FV, FXI, and FXIII deficiencies (data derived from
literature analysis)
Alloantibody Congenital FV
deficiency
Congenital FVII
deficiency
Congenital FXI
deficiency
Congenital FXIII
deficiency
Class IgG IgG IgG IgG, most frequently
directed against FXIII-A
subunit
Anaphylaxis No No No No
Titer Reported cases of low
and high inhibitor titer.
Anamnestic response
following FFP
Reported cases of low
and high inhibitor titer.
Anamnestic response
following rFVIIa
Reported cases of low
and high inhibitor titer.
Anamnestic response
following FXI
concentrate
NR. Anamnestic response
following FXIII
concentrate
Management Inhibitor eradication:
immunosuppressive
agents (steroids,
cyclophosphamide)
Treatment of bleeding:
FFP, platelet
concentrates, rFVIIa,
immunoadsorption,
plasmapheresis
Inhibitor eradication:
immunosuppressive
agents (steroids,
cyclophosphamide,
azathioprine,
immunoglobulin)
Treatment of bleeding:
rFVIIa
Inhibitor eradication:
immunosuppressive
agents (steroids,
cyclophosphamide)
Treatment of bleeding:
FXI concentrate (low
inhibitor titer), rFVIIa
Inhibitor eradication: ITI
(Malmö protocol)
Treatment of bleeding:
FXIII concentrate
Abbreviations: FFP, fresh frozen plasma; FV, factor V; FVII, factor VII; FXI, factor XI; FXIII, factor XIII; ITI, immune tolerance induction; NR, not reported;
rFVIIa, recombinant activated factor VII.
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is more extensively characterized than those of other defects,
perhaps due to the relatively high frequency of this defect and
small size of the gene.52 To date, more than 130 mutations
distributed throughout all the exons havebeendescribed,with
a considerable proportion of mutations located on exon 8,
which codes for the catalytic domain of FVII.53–56 Missense
mutations are the most frequent (70–80%), splicing-site
changes are also well represented, while nonsense mutations
and small deletions are rare.52 The severely deficient cases are
either homozygous or double heterozygous for mutations that
disruptexpressionof theprotein (i.e., deletionsand insertions),
resulting in FVII:C levels usually < 1% of normal. Individuals
with a mild/moderate clinical phenotype are homozygous or
doubly heterozygous formissensemutations.53 The identifica-
tion of FVII deficiency may be based on a prolonged PT with
normal aPTT, and diagnosis confirmed by reduced FVII:C by
modified one-stage PT-based clotting assay. Measurement of
plasma FVII:Ag by immunoassay is necessary to distinguish
qualitative from quantitative FVII deficiency.30
The severityof symptomsof FVII deficiency is quite variable
and reported to be poorly correlatedwith plasma levels. Some
patients with severe deficiency do not bleed after major
challenges of hemostasis. However, recent studies highlight
that the most severe bleeding symptoms are reported in
patients with FVII:C below 10% and that age and bleeding
pattern atdiagnosismaypredict thebleeding tendency in such
patients.49,57,58 Life- or limb-endangering bleedingmanifesta-
tions are relatively rare, the most frequent symptoms being
epistaxis and menorrhagia.59 The high incidence of central
nervous system bleeding (16%) reported by Ragni and collea-
gues48 in a series of 75patients affected by FVII deficiency,was
not confirmed by two subsequent studies.53,60 Thrombotic
episodes (particularly venous thrombosis), have also been
reported in3 to4%ofpatientswith FVII deficiency, particularly
in the presence of surgery and replacement treatment; how-
ever, spontaneous thrombosis may also occur.60,61
Current therapeutic options include fibrinolytic inhibitors,
fresh frozen plasma, prothrombin complex concentrates,
plasma-derived FVII concentrates and rFVIIa.30 However, the
very short half-life of FVII makes it difficult to use fresh frozen
plasma without causing volume overload. Recombinant FVIIa
has to be considered the optimal replacement therapy since it
can be used at a very low dose (15–30 μg/kg).62–64
Anti-FVII Alloantibodies
Rarely, replacement therapy of severe inherited FVII deficiency
is complicated by the occurrence of inhibitors against infused
FVII.30 Thirteen inhibitor cases have been reported so far in
eight studies, following use of either plasma-derived or rFVII
products.65–72 In a prospective study of 101 spontaneous or
traumatic bleeds occurring in 75 patients with congenital FVII
deficiency, two inhibitors were detected in two repeatedly
treated patients (one post-plasma-derived FVII, one post-
rFVIIa).67 See and colleagues72 reported the case of FVII in-
hibitordevelopment following liver transplantation ina5-year-
oldgirlwith severe congenital FVII deficiency. Interestingly, she
was responsive to rFVIIa despite thepresence of the inhibitor.72
Also, successful prophylactic rFVIIa in a patient with inherited
FVII deficiency with inhibitors to FVII was reported by Tokgoz
and colleagues,68 suggesting a possible weak affinity of this
alloantibody to rFVIIa. By contrast, Borhany and colleagues71
reported a FVII inhibitor case who did not respond to rFVIIa
therapy despite extensive immunosuppressive (methylpredni-
solone and cyclophosphamide) treatment. The largest experi-
ence is that by Batorova and colleagues on behalf of the STER
(Seven Treatment Evaluation Registry) study group,70 who
detected FVII inhibitors in 2.6% (3/115) of patients in the
registry. All inhibitors were high responders, and all but one
were detected in infants with a severe FVII defect and bleeding
phenotype.
Alloantibodies in Congenital FXI Deficiency
Characteristics of Congenital FXI Deficiency
FXI is a dimeric serine protease mainly synthesized in the
liver and encoded by the 23 kb long FXI gene located on
chromosome 4.73 Hereditary FXI deficiency is an autosomal
bleeding disorder characterized by reduced levels of FXI in
plasma and typically manifests as a prolongation of the aPTT
with reduced FXI activity, as determined by one-stage mod-
ified aPTT clotting assay.74–76 The prevalence of severe FXI
deficiency is approximately 1:1,000,000, although it has
been reported to be much in Ashkenazi Jews.77 Nearly 200
different mutations affecting the FXI gene have been identi-
fied so far, missense mutations representing more than 60%
of all variants.30,78 Two mutations are responsible for most
cases of FXI deficiency in Ashkenazi Jews, while mutations
aremore varied in non-Jews.78,79 The type II Jewishmutation
is a stop codon in exon 5, leading to undetectable FXI levels in
homozygous individuals. The type III Jewish mutation is a
missensemutation in exon 9 that causes a defective secretion
of the protein from cells, but some FXI is ultimately produced
so that measurable levels of FXI (at 10%) are present in
these patients. Type II/III compound heterozygosity is the
commonest cause of severe to moderate FXI deficiency in
Ashkenazi Jews.80
In comparisonwith hemophilia A or B, bleedingmanifesta-
tions in FXI deficiency are much less predictable, even in
patients with severe deficiency. Bleeding is not related to
FXI plasma levels but rather to the site of injury. Thus, the
risk of bleeding is increasedwhen at a site of injury with local
high fibrinolytic activity (e.g., oral cavity after dental extrac-
tion or tonsillectomy, urogenital tract).81 Patients with severe
FXI deficiency are usually mildly affected and most bleeding
manifestations are injury-related. Patients with low but de-
tectable levelsof FXI are also surprisinglymildbleeders, so that
in these two groups clinical phenotypes are not strikingly
different.82Womenwith FXI deficiency are prone to excessive
bleeding during menstruation, but case series of women
affected by severe FXI deficiency showed that 70% of pregnan-
cies were uneventful, despite no prophylactic treatment.83,84
Treatment of congenital FXI deficiency is based upon the
use of antifibrinolytic agents, fresh-frozen plasma, plasma-
derived FXI concentrate and rFVIIa, but attention should be
paid to reduce the riskof thrombotic complications (especially
when FXI concentrates are employed), volume overloadwhen
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fresh frozen plasma is used, and allergic reactions and devel-
opment of inhibitors following FXI replacement therapy (see
below).73 As surgery or trauma can be associated with
excessive and prolonged bleeding unless adequately treated,
a careful evaluation of patients with severe FXI deficiency is
recommended prior to surgery, aswell asmeticulousplanning
of the procedure and of the post-surgical course. FXI has a
relatively long half-life (40–70 hours), so that the infusion of
15 to 20 mL/kg virus-inactivated fresh frozen plasma on
alternate days should be sufficient to keep FIX at trough
hemostatic levels of 15 to 20%.85
Anti-FXI Alloantibodies
A severe complication of replacement therapy in congenital
FXI deficiency is the development of inhibitor to infused
FXI.86,87 In a study conducted in 2003 by Salomon and
colleagues on 188 Israeli patients with severe FXI deficiency,
7 of 21 patients (33%) homozygous for type II mutation
developed inhibitors after exposure to plasma.88 Character-
ization of these inhibitors revealed that they were all IgG
alloantibodies and inhibited activation of FXI by thrombin or
activated factor XII (FXIIa) and inhibited activation of FIX by
exogenous FXIa.88 Patients with FXI deficiency do not bleed
spontaneously. Nevertheless, FXI inhibitors may increase
surgical- or trauma-related bleeding and reduce responses
to FXI replacement.86 Thus, the presence of an inhibitor
should be suspected (and investigated) when replacement
therapy with fresh frozen plasma or FXI concentrate fails to
correct a prolonged aPTT or when a patient continues to
bleed despite appropriate treatment. In such cases, aPTT
mixing studies and the modified Bethesda assay are helpful
to detect and quantify the FXI inhibitor.88 In addition, a
periodical screening for inhibitor is mandatory in patients
with severe FXI deficiency due to null mutations, especially if
a surgical procedure is planned.30
Pertaining to the treatment of inhibitor patients, when
the titer of inhibitor is low, the use of FXI concentratemay be
hemostatically sufficient, although an anamnestic response
is to be expected.75 Since the first successful report by
Hedner and colleagues in 1990,89 several authors have
reported effective hemostatic treatment of severe FXI
deficiency and inhibitors using rFVIIa at doses varying be-
tween 30 and 90 μg/kg.90–93 More recently, Livnat and
colleagues94 observed that relatively low concentrations of
rFVIIa corrected in vitro thrombin generation in plasma from
patients with severe FXI deficiency and an inhibitor. On the
basis of this finding, the same authors treated three patients
with severe FXI deficiency and FXI inhibitorswho underwent
major surgery with a single low dose of rFVIIa (15–30 μg/kg)
and tranexamic acid and this protocol secured normal
hemostasis without thrombotic adverse events.95 All in all,
these data suggest that rFVIIa in patients with severe FXI
deficiency and inhibitors may induce effective hemostasis
at doses that are lower than those required for patients
with severe hemophilia A or B and inhibitors.96 Finally,
successful inhibitor eradication with immunosuppressive
therapy (cyclophosphamide and steroids) has been reported
by Teruya and Styler.97
Alloantibodies in Congenital FXIII Deficiency
Characteristics of Congenital FXIII Deficiency
FXIII, also calledfibrin-stabilizing factor, is the last enzymetobe
activated in the blood coagulation pathway and functions to
crosslinkα- and γ-fibrin chains, resulting in a stronger clot with
an increased resistance to fibrinolysis.98,99 The plasma factor
consists of two catalytic A subunits (FXIII-A) and two carrier B
subunits (FXIII-B). FXIII-A issynthesized in cells of bonemarrow
origin, while FXIII-B is produced in the liver. The corresponding
genes are located on chromosome6 and 1.100,101 Inherited FXIII
deficiency is an autosomal recessive disorder with a frequency
ofapproximately1:2,000,000 in thegeneralpopulation.Routine
coagulation screening tests (PT, aPTT and platelet count) are
usually normal, and traditionally the diagnosis of FXIII defi-
ciency has been established by the demonstration of increased
clot solubility ina5 Mureaor1%monochloracetic acid solution.
However, such assays may not reliably identify FXIII-deficient
patients, and functional or specific immunoassay tests that
measure FXIII-A and FXIII-B antigen levels have been devel-
oped.100,102 More than one hundred different mutations have
been identified so far in the FXIII registry database (available at:
http://www.f13-database.de, accessed March 7, 2017), with
missense mutations being those most commonly reported for
both genes, although themajority of such defects are identified
in the A-subunit, scattered throughout the F13A gene.101 Pa-
tientswith severe disease characterizedby lowplasma levels of
FXIII can have homozygous mutations or compound hetero-
zygous mutations.103
Individuals with FXIII deficiency have an increased ten-
dency to bleed.104 Animal models of severe FXIII deficiency
present with intrathoracic, intraperitoneal and subcutaneous
hemorrhage.105 Inhumans, bleeding fromtheumbilical stump
in the first few days of life is common. Intracranial hemor-
rhage, ecchymoses, hematomas and prolonged bleeding
following trauma are also characteristic.106 Delayed wound
healing was reported in approximately 30% of FXIII-deficient
patients, while hemarthroses and bleeding into the muscles
are less common than in hemophiliacs.107 In a study using
the largest group of patients with severe FXIII deficiency
(93 Iranians) the most frequent mucosal tract bleeding symp-
tom was bleeding in the oral cavity (lips, tongue, gum)
followed by menorrhagia and epistaxis.106 Twenty percent
of patients in the reproductive age had intraperitoneal bleed-
ing at the timeofovulation,while 50% of pregnant womenhad
at least one miscarriage.106
The clinical severity of FXIII deficiency prompts regular
prophylaxis.98 This mode of treatment is facilitated by hemo-
static levels of FXIII as low as 2 to 5%; given the very long
plasma half-life of infused FXIII (11–14 days), replacement
material can be infused at large intervals (20–30 days).108
During pregnancies, monthly prophylactic infusions of FXIII
concentrate are necessary to prevent abortions. There are two
types of FXIII-containing products: a plasma-derived FXIII
concentrate and a recombinant FXIII-A2 product.108,109While
the former is appropriate forpatientswitheitherAorB subunit
deficiency, the recombinant FXIII-A2 concentrate (which con-
tains only the FXIII-A subunit) is only suitable for patientswith
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FXIII-A subunit deficiency; however, this reflects themajority
of such cases of this congenital bleeding disorder.110–112
Anti-FXIII Alloantibodies
Besides severe acquired FXIII deficiency caused by an auto-
antibody against either of the FXIII subunits,100 an anti-FXIII
antibody may also develop in patients with inherited FXIII
deficiency under replacement therapy. The incidence of such
alloantibodies is unknown, although it seems to be a very
rare event. Indeed, only seven cases of anti-FXIII-A alloanti-
bodies have been reported so far in the literature,113–119
while there is only a single report on anti-FXIII-B alloanti-
bodies.120 The most recent report was that published by
Penzes and colleagues in 2016.119 The investigators charac-
terized the anti-FXIII-A alloantibody, isolated from a patient
with a severe FXIII-A deficiency and bleeding phenotype,
demonstrating that it belonged to IgG class and exerted a
multiple inhibitory effect on FXIII activation (interference
with thrombin and Ca2þ-induced FXIII activation) and activ-
ity (interference with the transglutaminase activity of acti-
vated FXIII).119 Also, the alloantibody was responsible for an
accelerated clearance of administered plasma-derived FXIII
concentrate from the circulation. Attempts to eliminate the
alloantibody through ITI treatment (Malmö protocol includ-
ing cyclophosphamide, IVIG, and high-dose FXIII) resulted
only in a transient improvement, and the patients died due to
intracerebral hemorrhage.119 Wada and colleagues120 re-
ported the case of a patient with severe congenital FXIII-B
deficiency, whose mild bleeding phenotype was aggravated
by the development of an anti-FXIII-B alloantibody. Finally,
in a multicenter phase III trial in 41 patients with congenital
FXIII-A subunit deficiency treatedwith recombinant FXIII-A2
product, 4 patients developed transient, non-neutralizing,
low-titer anti-FXIII antibodies.121
Conclusion
The development of inhibitory alloantibodies following re-
placement therapy in patients with inherited rare bleeding
disorders is a very unusual adverse event, occurring much
less frequently than reported in patients with congenital
severe hemophilia A treated with FVIII concentrates, or even
those with congenital severe hemophilia B treated with FIX
concentrates. Nevertheless, the management of such rare
inhibitors is perhaps even more challenging for caregivers of
HTCs, especially considering that the published experience
upon which to base their clinical practice is scanty. In this
regard, while very little is known about treatments aiming to
eliminate these inhibitors, rFVIIa seems to be the most
universally acceptable therapeutic option for managing
bleeding (except for FXIII deficiency, ►Table 1). The imple-
mentation of international registries aimed at recording
additional inhibitor cases and improving our knowledge on
their management is greatly welcomed.
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